If your company is struggling to secure its next round of funding, have you asked yourself why?
The answer may involve more than difficult capital markets.
Developing a new drug or medical device takes time. Clinical studies, regulatory requirements, manufacturing challenges, patient recruitment, and unexpected setbacks can extend timelines and increase costs.
Every additional month consumes capital.
And every additional month gives competitors an opportunity to advance.
For pharmaceutical and medical device leadership, there are two clocks running simultaneously.
The FDA clock: How long will it take to generate the evidence needed for regulatory approval, clearance, or authorization?
The investment clock: How long will existing capital last, and what must the company demonstrate to attract its next financing?
Those clocks do not necessarily move together.
A company can make genuine regulatory progress while its investment attractiveness declines.
Consider a company developing a promising immunology drug or an innovative diagnostic device. Its development program is progressing, yet significant regulatory and market-access milestones may still be years away.
During that time, an established competitor could gain approval for a new indication. Another company could introduce a more convenient treatment or diagnostic technology. Physician practices could change. Payers could impose new restrictions, or a lower-cost alternative could become available.
The original innovation might remain clinically valuable.
The question is whether the market opportunity supporting its original valuation will still exist when the product is ready for patients.
That question becomes especially important when another financing round is needed to complete development.
Investors must consider not only the probability of regulatory success, but also the capital required to reach it and the value the asset could command along the way.
Several factors can materially influence that assessment:
- Time to market: What additional studies, regulatory requirements, or manufacturing milestones could extend development?
- Competitive developments: Which drugs, devices, or diagnostic technologies could enter the market first?
- Realistic patient opportunity: How many patients could actually receive or benefit from the innovation, rather than simply qualify based on disease prevalence?
- Physician and institutional adoption: What would persuade clinicians, hospitals, and healthcare systems to change established practices?
- Payer access and reimbursement: Will coverage, payment levels, and treatment economics support adoption?
- Investment and licensing value: How might these considerations affect the asset's attractiveness to investors and prospective licensing partners today?
These are not questions that begin after FDA approval or clearance.
They influence decisions about financing, development priorities, and the use of limited capital right now.
A delay in financing can create its own consequences. It may force a company to reduce development activities, postpone studies, accept less favorable financing terms, or reconsider its strategic options.
The result can be a difficult cycle: additional time requires additional capital, while changes in the competitive landscape may make that capital harder to attract.
Of course, financing challenges do not automatically indicate a problem with the asset. Market conditions, investor risk tolerance, and capital availability can affect even promising programs.
The important distinction is whether investors are hesitating because capital is scarce—or because the asset's future value has not been sufficiently established.
Those are different problems, requiring different responses.
My recent work reviewing emerging pharmaceutical and medical technology programs has reinforced the importance of evaluating investment and licensing value against the treatment and diagnostic landscape an asset is likely to encounter—not simply the market that exists today.
The longer development takes, the more important those assumptions become.
Time to regulatory approval or clearance matters. Time to financing matters. And the market opportunity can change while both clocks are running.
Before pursuing the next financing round, company leadership should consider one additional question:
Have we demonstrated not only why our innovation deserves to advance, but why its future market opportunity justifies the investment required today?
Investment Value Today. Licensing Value Tomorrow.